The MMP-2 substrate acts as active targeting to the TME due to the overexpression of metalloproteinases and the cis-aconityl linkage allows for controlled release of DOX on site due to the tumor acidic hydrolyzed of the bonds. The gene discussed is MMP2; the disease is neoplasm.